OSE Immunotherapeutics targets mid-2027 validation for subcutaneous lusvertikimab in IBD
Phase I study submission for the subcutaneous formulation is slated for end-2026, with results expected by mid-2027.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
3 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
OSE Immunotherapeutics SA (OSE) To Present Combi-TED Phase 2 Topline Results at ESMO 2026
OSE Immunotherapeutics SA said topline results from the Phase 2 Combi-TED trial of Tedopi in metastatic NSCLC were selected for oral presentation at ESMO 2026. The study tested Tedopi plus nivolumab or docetaxel vs docetaxel alone as second-line therapy.Material DetailsContext by AI AnalystThis is…
OSE Immunotherapeutics Announces Presentation of Combi-TED Phase 2 Topline Results of Tedopi® in Non-Small Cell Lung Cancer at the ESMO 2026 Meeting
Nantes, France, September 23, 2026 — 7:30am CET — OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), a clinical-stage biotech company dedicated to developing first-in-class therapies in immuno-oncology and immuno-inflammation, today announced that topline results from the Combi-TED Phase 2…